Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphatic Vessels | 12 | 2019 | 356 | 3.080 |
Why?
|
Neovascularization, Pathologic | 38 | 2024 | 2634 | 2.770 |
Why?
|
Stress, Mechanical | 20 | 2024 | 1680 | 2.260 |
Why?
|
Lymphatic System | 7 | 2019 | 251 | 2.030 |
Why?
|
Models, Biological | 27 | 2024 | 9499 | 1.630 |
Why?
|
Neovascularization, Physiologic | 12 | 2024 | 1371 | 1.490 |
Why?
|
Blood Vessels | 14 | 2021 | 1110 | 1.470 |
Why?
|
Neoplasms | 46 | 2024 | 22390 | 1.410 |
Why?
|
Mechanotransduction, Cellular | 6 | 2024 | 542 | 1.330 |
Why?
|
Extracellular Fluid | 5 | 2022 | 165 | 1.310 |
Why?
|
Microfluidic Analytical Techniques | 5 | 2015 | 823 | 1.110 |
Why?
|
Erythrocytes | 10 | 2011 | 2421 | 0.940 |
Why?
|
Neoplasm Metastasis | 12 | 2019 | 4926 | 0.930 |
Why?
|
Tumor Microenvironment | 14 | 2024 | 3951 | 0.890 |
Why?
|
Leukocytes | 9 | 2013 | 2034 | 0.810 |
Why?
|
Blood Flow Velocity | 7 | 2010 | 1376 | 0.760 |
Why?
|
Lymph | 2 | 2019 | 78 | 0.760 |
Why?
|
Models, Cardiovascular | 6 | 2012 | 983 | 0.730 |
Why?
|
Cell Adhesion | 20 | 2013 | 3102 | 0.700 |
Why?
|
Hemorheology | 8 | 2018 | 144 | 0.700 |
Why?
|
Endothelium, Vascular | 17 | 2023 | 4428 | 0.670 |
Why?
|
Neoplasms, Experimental | 5 | 2016 | 1231 | 0.660 |
Why?
|
Models, Immunological | 1 | 2022 | 518 | 0.660 |
Why?
|
Cell Communication | 6 | 2013 | 1660 | 0.640 |
Why?
|
Hemodynamics | 5 | 2024 | 4199 | 0.620 |
Why?
|
Lymphedema | 2 | 2016 | 526 | 0.610 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2021 | 410 | 0.610 |
Why?
|
Secretory Leukocyte Peptidase Inhibitor | 1 | 2018 | 23 | 0.600 |
Why?
|
Laser Therapy | 1 | 2024 | 1110 | 0.550 |
Why?
|
Lymphokines | 6 | 2009 | 927 | 0.540 |
Why?
|
Biocompatible Materials | 2 | 2023 | 1703 | 0.530 |
Why?
|
Implants, Experimental | 1 | 2016 | 99 | 0.520 |
Why?
|
Cell Aggregation | 4 | 2009 | 238 | 0.510 |
Why?
|
Neoplasm Invasiveness | 6 | 2019 | 3629 | 0.510 |
Why?
|
Endothelial Growth Factors | 6 | 2002 | 674 | 0.510 |
Why?
|
Tissue Culture Techniques | 1 | 2016 | 290 | 0.500 |
Why?
|
Microvessels | 4 | 2024 | 586 | 0.500 |
Why?
|
Lymphangiogenesis | 2 | 2016 | 171 | 0.490 |
Why?
|
Cell Movement | 18 | 2019 | 5216 | 0.490 |
Why?
|
Animals | 103 | 2024 | 169408 | 0.490 |
Why?
|
Capillary Permeability | 7 | 2013 | 773 | 0.480 |
Why?
|
Endothelial Cells | 12 | 2024 | 3591 | 0.480 |
Why?
|
Microcirculation | 8 | 2010 | 1281 | 0.470 |
Why?
|
Angiogenesis Inhibitors | 11 | 2023 | 2059 | 0.470 |
Why?
|
Lymphatic Metastasis | 6 | 2016 | 2916 | 0.460 |
Why?
|
Vascular Endothelial Growth Factor A | 17 | 2024 | 3518 | 0.450 |
Why?
|
Organ Culture Techniques | 1 | 2016 | 796 | 0.440 |
Why?
|
Mice | 70 | 2024 | 82074 | 0.440 |
Why?
|
Rheology | 3 | 2011 | 348 | 0.430 |
Why?
|
Metabolic Diseases | 1 | 2020 | 684 | 0.430 |
Why?
|
Dimethylpolysiloxanes | 4 | 2016 | 143 | 0.430 |
Why?
|
Colonic Neoplasms | 7 | 2005 | 2543 | 0.410 |
Why?
|
Biological Transport | 1 | 2016 | 2085 | 0.400 |
Why?
|
rhoA GTP-Binding Protein | 2 | 2012 | 237 | 0.390 |
Why?
|
Androgen Antagonists | 1 | 2021 | 1421 | 0.390 |
Why?
|
Arteriovenous Anastomosis | 1 | 2011 | 14 | 0.390 |
Why?
|
Antineoplastic Agents | 10 | 2023 | 13699 | 0.380 |
Why?
|
Mammary Neoplasms, Experimental | 4 | 2009 | 506 | 0.370 |
Why?
|
Platelet-Derived Growth Factor | 3 | 2009 | 617 | 0.360 |
Why?
|
Endothelium | 2 | 2011 | 768 | 0.360 |
Why?
|
Edema | 2 | 2022 | 766 | 0.360 |
Why?
|
Hematocrit | 6 | 2010 | 623 | 0.350 |
Why?
|
Lymphography | 5 | 2014 | 189 | 0.340 |
Why?
|
Biomimetic Materials | 1 | 2011 | 173 | 0.340 |
Why?
|
Pressure | 4 | 2022 | 1172 | 0.330 |
Why?
|
Mice, SCID | 17 | 2017 | 2631 | 0.330 |
Why?
|
Immunotherapy, Adoptive | 2 | 2019 | 1519 | 0.330 |
Why?
|
Blood Cells | 1 | 2011 | 309 | 0.330 |
Why?
|
Nitric Oxide | 6 | 2019 | 2149 | 0.320 |
Why?
|
Cell Culture Techniques | 4 | 2024 | 1667 | 0.310 |
Why?
|
Cell Shape | 2 | 2009 | 371 | 0.310 |
Why?
|
Humans | 115 | 2024 | 768887 | 0.300 |
Why?
|
Pancreatic Neoplasms | 5 | 2019 | 5443 | 0.300 |
Why?
|
Computer Simulation | 8 | 2024 | 6289 | 0.290 |
Why?
|
Atherosclerosis | 1 | 2023 | 3431 | 0.280 |
Why?
|
Models, Theoretical | 8 | 2024 | 3580 | 0.280 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 4 | 2005 | 692 | 0.280 |
Why?
|
Cholangiocarcinoma | 2 | 2024 | 562 | 0.280 |
Why?
|
Collagen | 8 | 2024 | 2646 | 0.270 |
Why?
|
Cell Line, Tumor | 18 | 2021 | 17174 | 0.270 |
Why?
|
Neoplasm Transplantation | 11 | 2012 | 2018 | 0.260 |
Why?
|
Blood Vessel Prosthesis | 1 | 2011 | 957 | 0.260 |
Why?
|
Cell Separation | 2 | 2011 | 1728 | 0.260 |
Why?
|
Blood Volume | 1 | 2007 | 546 | 0.260 |
Why?
|
Immunotherapy | 6 | 2023 | 4755 | 0.260 |
Why?
|
Extracellular Matrix | 6 | 2018 | 1739 | 0.250 |
Why?
|
Capillaries | 2 | 2012 | 756 | 0.250 |
Why?
|
Glycocalyx | 2 | 2019 | 99 | 0.250 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 5 | 2024 | 550 | 0.240 |
Why?
|
Blood Physiological Phenomena | 1 | 2004 | 53 | 0.240 |
Why?
|
Microscopy, Fluorescence | 13 | 2018 | 2635 | 0.240 |
Why?
|
Liver | 2 | 2020 | 7579 | 0.240 |
Why?
|
Biophysical Phenomena | 5 | 2018 | 320 | 0.230 |
Why?
|
Mathematical Concepts | 1 | 2024 | 75 | 0.230 |
Why?
|
Proteoglycans | 3 | 2024 | 809 | 0.230 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2006 | 368 | 0.230 |
Why?
|
Stem Cells | 4 | 2024 | 3540 | 0.230 |
Why?
|
Disease Progression | 7 | 2024 | 13677 | 0.220 |
Why?
|
Venules | 2 | 2003 | 161 | 0.220 |
Why?
|
Dental Pulp | 1 | 2024 | 86 | 0.220 |
Why?
|
Polyethylene Glycols | 2 | 2014 | 1197 | 0.210 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2023 | 1339 | 0.210 |
Why?
|
Vasculitis | 1 | 2007 | 525 | 0.210 |
Why?
|
Tumor Cells, Cultured | 10 | 2016 | 6131 | 0.210 |
Why?
|
Microscopy, Confocal | 7 | 2010 | 1973 | 0.210 |
Why?
|
Microfluidics | 4 | 2011 | 674 | 0.200 |
Why?
|
Muscle Contraction | 2 | 2019 | 1209 | 0.200 |
Why?
|
Ear | 2 | 2012 | 172 | 0.190 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2006 | 703 | 0.190 |
Why?
|
Pseudopodia | 2 | 2012 | 167 | 0.190 |
Why?
|
Cell Survival | 6 | 2020 | 5794 | 0.190 |
Why?
|
Stress, Physiological | 2 | 2019 | 1410 | 0.190 |
Why?
|
Equipment Design | 4 | 2016 | 3529 | 0.190 |
Why?
|
Muscle Cells | 2 | 2019 | 195 | 0.190 |
Why?
|
Mammary Glands, Animal | 2 | 2012 | 273 | 0.180 |
Why?
|
Cell Adhesion Molecules | 4 | 2016 | 1614 | 0.180 |
Why?
|
Umbilical Veins | 5 | 2011 | 425 | 0.180 |
Why?
|
Adenocarcinoma | 6 | 2012 | 6401 | 0.180 |
Why?
|
Blood Viscosity | 3 | 2007 | 125 | 0.170 |
Why?
|
Osmolar Concentration | 2 | 2019 | 657 | 0.170 |
Why?
|
Hyaluronic Acid | 4 | 2014 | 488 | 0.170 |
Why?
|
Pregnancy Proteins | 1 | 2001 | 222 | 0.170 |
Why?
|
Microscopy | 5 | 2019 | 909 | 0.170 |
Why?
|
Calcium | 3 | 2019 | 5792 | 0.170 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2006 | 1493 | 0.170 |
Why?
|
Chemokine CXCL10 | 1 | 2020 | 312 | 0.160 |
Why?
|
Ammonia | 1 | 2020 | 248 | 0.160 |
Why?
|
Mechanical Phenomena | 1 | 2020 | 143 | 0.160 |
Why?
|
Hep G2 Cells | 1 | 2020 | 378 | 0.160 |
Why?
|
Glioblastoma | 5 | 2019 | 3525 | 0.160 |
Why?
|
Drug Delivery Systems | 4 | 2019 | 2238 | 0.160 |
Why?
|
Monte Carlo Method | 1 | 2024 | 1262 | 0.160 |
Why?
|
Arteries | 1 | 2024 | 1126 | 0.160 |
Why?
|
Glypicans | 1 | 2019 | 33 | 0.160 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2018 | 8664 | 0.160 |
Why?
|
Liposomes | 1 | 2002 | 792 | 0.160 |
Why?
|
Breast Implants | 2 | 2012 | 414 | 0.160 |
Why?
|
Tensile Strength | 1 | 2019 | 335 | 0.160 |
Why?
|
Inflammation | 3 | 2018 | 10869 | 0.150 |
Why?
|
T-Lymphocytes | 7 | 2023 | 10276 | 0.150 |
Why?
|
Prostatic Neoplasms | 2 | 2021 | 11229 | 0.150 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2017 | 719 | 0.150 |
Why?
|
Kinetics | 5 | 2019 | 6334 | 0.150 |
Why?
|
Antibodies, Bispecific | 2 | 2016 | 205 | 0.150 |
Why?
|
Urea | 1 | 2020 | 448 | 0.150 |
Why?
|
Morphogenesis | 2 | 2012 | 747 | 0.150 |
Why?
|
Oxygen | 4 | 2020 | 4273 | 0.150 |
Why?
|
Cisplatin | 1 | 2024 | 1661 | 0.150 |
Why?
|
Drug Combinations | 1 | 2024 | 2088 | 0.150 |
Why?
|
Antigens, Neoplasm | 2 | 2023 | 2001 | 0.150 |
Why?
|
Disease Models, Animal | 13 | 2023 | 18366 | 0.150 |
Why?
|
Albumins | 1 | 2020 | 577 | 0.140 |
Why?
|
Cardiovascular Diseases | 1 | 2023 | 15662 | 0.140 |
Why?
|
Blood Pressure | 3 | 2008 | 8541 | 0.140 |
Why?
|
Phenylurea Compounds | 1 | 2020 | 531 | 0.140 |
Why?
|
Bioengineering | 1 | 2018 | 101 | 0.140 |
Why?
|
Elasticity | 2 | 2018 | 657 | 0.140 |
Why?
|
High-Throughput Screening Assays | 1 | 2023 | 941 | 0.140 |
Why?
|
Carcinoma, Renal Cell | 3 | 2019 | 3200 | 0.140 |
Why?
|
Breast Neoplasms | 7 | 2019 | 21187 | 0.140 |
Why?
|
Adaptive Immunity | 2 | 2024 | 733 | 0.140 |
Why?
|
Biomedical Engineering | 1 | 2018 | 286 | 0.130 |
Why?
|
Vascular Endothelial Growth Factors | 5 | 2001 | 750 | 0.130 |
Why?
|
Heparan Sulfate Proteoglycans | 1 | 2016 | 111 | 0.130 |
Why?
|
Systems Biology | 1 | 2020 | 482 | 0.130 |
Why?
|
Antibodies, Neoplasm | 2 | 2016 | 283 | 0.130 |
Why?
|
Cells, Cultured | 12 | 2024 | 19023 | 0.130 |
Why?
|
Stromal Cells | 4 | 2016 | 1337 | 0.130 |
Why?
|
Apoptosis | 3 | 2009 | 9528 | 0.130 |
Why?
|
Fluorometry | 1 | 1995 | 99 | 0.130 |
Why?
|
Lithium | 1 | 2019 | 600 | 0.130 |
Why?
|
Ribonuclease, Pancreatic | 1 | 2016 | 112 | 0.120 |
Why?
|
Carbon Dioxide | 1 | 2020 | 1149 | 0.120 |
Why?
|
Biological Assay | 1 | 2018 | 628 | 0.120 |
Why?
|
Kidney Neoplasms | 3 | 2019 | 4300 | 0.120 |
Why?
|
Clinical Trials as Topic | 2 | 2022 | 8055 | 0.120 |
Why?
|
Hypertension, Pulmonary | 1 | 2006 | 1600 | 0.120 |
Why?
|
Patient Positioning | 1 | 2018 | 332 | 0.120 |
Why?
|
Bile Duct Neoplasms | 1 | 2021 | 615 | 0.120 |
Why?
|
Regeneration | 1 | 2024 | 1524 | 0.120 |
Why?
|
Transplantation, Heterologous | 6 | 2010 | 2395 | 0.120 |
Why?
|
Pathology | 1 | 2018 | 270 | 0.120 |
Why?
|
Endothelium, Lymphatic | 1 | 2015 | 63 | 0.120 |
Why?
|
Pharmaceutical Preparations | 1 | 2023 | 1088 | 0.120 |
Why?
|
Neoplasm Proteins | 3 | 2017 | 3608 | 0.120 |
Why?
|
Viral Load | 1 | 2024 | 3398 | 0.120 |
Why?
|
Rats | 12 | 2019 | 23847 | 0.120 |
Why?
|
Elastomers | 1 | 2015 | 69 | 0.120 |
Why?
|
Vesicular Transport Proteins | 2 | 2016 | 377 | 0.120 |
Why?
|
Staining and Labeling | 6 | 2013 | 1081 | 0.120 |
Why?
|
Angiopoietin-2 | 2 | 2019 | 185 | 0.120 |
Why?
|
Melanoma, Experimental | 3 | 2005 | 559 | 0.120 |
Why?
|
Losartan | 1 | 2016 | 262 | 0.120 |
Why?
|
Wound Healing | 3 | 2012 | 2815 | 0.110 |
Why?
|
Mice, Nude | 8 | 2019 | 3631 | 0.110 |
Why?
|
Cell Proliferation | 2 | 2009 | 10486 | 0.110 |
Why?
|
Lung Neoplasms | 3 | 2018 | 13593 | 0.110 |
Why?
|
Brain Neoplasms | 5 | 2020 | 9213 | 0.110 |
Why?
|
Lower Extremity | 1 | 2022 | 1217 | 0.110 |
Why?
|
Immune System | 2 | 2016 | 800 | 0.110 |
Why?
|
Immunologic Techniques | 1 | 1993 | 213 | 0.110 |
Why?
|
Perfusion | 3 | 2019 | 1402 | 0.110 |
Why?
|
Antibodies | 3 | 2008 | 2422 | 0.110 |
Why?
|
Diagnostic Imaging | 3 | 2014 | 3538 | 0.110 |
Why?
|
Hepatocytes | 1 | 2020 | 1246 | 0.110 |
Why?
|
Contrast Media | 2 | 2018 | 5334 | 0.100 |
Why?
|
Tail | 1 | 2012 | 90 | 0.100 |
Why?
|
Cell-Matrix Junctions | 1 | 2011 | 21 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 7 | 2016 | 3621 | 0.100 |
Why?
|
Shear Strength | 2 | 2013 | 160 | 0.100 |
Why?
|
Anterior Chamber | 1 | 2012 | 194 | 0.100 |
Why?
|
Algorithms | 2 | 2024 | 14199 | 0.100 |
Why?
|
Lung | 3 | 2008 | 10097 | 0.090 |
Why?
|
Lipids | 1 | 2002 | 3345 | 0.090 |
Why?
|
Cytoskeleton | 3 | 2011 | 1180 | 0.090 |
Why?
|
Lymphocytes | 4 | 2002 | 2614 | 0.090 |
Why?
|
Matrix Metalloproteinase 14 | 1 | 2011 | 59 | 0.090 |
Why?
|
Tissue Engineering | 3 | 2011 | 1893 | 0.090 |
Why?
|
Sepharose | 2 | 2009 | 102 | 0.090 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 703 | 0.090 |
Why?
|
Liver Neoplasms | 2 | 2020 | 4363 | 0.090 |
Why?
|
Actomyosin | 1 | 2011 | 114 | 0.090 |
Why?
|
Macrophages | 2 | 2016 | 5800 | 0.090 |
Why?
|
Lymphatic Diseases | 1 | 2012 | 319 | 0.090 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2024 | 4651 | 0.090 |
Why?
|
Otologic Surgical Procedures | 1 | 2012 | 150 | 0.090 |
Why?
|
Pericytes | 2 | 2011 | 299 | 0.090 |
Why?
|
Fluorescent Dyes | 6 | 2013 | 1933 | 0.090 |
Why?
|
Immunohistochemistry | 7 | 2018 | 11119 | 0.090 |
Why?
|
Spheroids, Cellular | 3 | 2016 | 331 | 0.090 |
Why?
|
Pancreatic Ducts | 1 | 2012 | 330 | 0.090 |
Why?
|
Adipose Tissue | 2 | 2012 | 3335 | 0.090 |
Why?
|
Fluorescent Antibody Technique | 1 | 2015 | 2475 | 0.090 |
Why?
|
Integrin alpha3 | 2 | 2013 | 26 | 0.090 |
Why?
|
Immune Tolerance | 1 | 2019 | 2323 | 0.090 |
Why?
|
Radionuclide Imaging | 1 | 2014 | 1998 | 0.090 |
Why?
|
Static Electricity | 1 | 2010 | 261 | 0.080 |
Why?
|
Fibroblasts | 3 | 2016 | 4178 | 0.080 |
Why?
|
Biophysics | 3 | 2002 | 379 | 0.080 |
Why?
|
Deoxycytidine | 1 | 2014 | 888 | 0.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 11886 | 0.080 |
Why?
|
Gels | 1 | 2010 | 422 | 0.080 |
Why?
|
Diffusion | 4 | 2013 | 818 | 0.080 |
Why?
|
Vascular Endothelial Growth Factor C | 2 | 2007 | 125 | 0.080 |
Why?
|
Membrane Glycoproteins | 1 | 2000 | 3714 | 0.080 |
Why?
|
Cell Division | 5 | 2004 | 4478 | 0.080 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2014 | 752 | 0.080 |
Why?
|
Pyridines | 1 | 2020 | 2896 | 0.080 |
Why?
|
Anastomosis, Surgical | 1 | 2012 | 994 | 0.080 |
Why?
|
Particle Size | 3 | 2010 | 1652 | 0.080 |
Why?
|
Materials Testing | 1 | 2012 | 873 | 0.080 |
Why?
|
Neurofibromatosis 2 | 1 | 2012 | 388 | 0.080 |
Why?
|
Time Factors | 12 | 2012 | 40266 | 0.080 |
Why?
|
Neurofibromatoses | 1 | 2012 | 303 | 0.070 |
Why?
|
NF-kappa B | 1 | 2016 | 2492 | 0.070 |
Why?
|
Neutrophils | 1 | 2001 | 3785 | 0.070 |
Why?
|
Glucose | 1 | 2020 | 4352 | 0.070 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2020 | 2336 | 0.070 |
Why?
|
Molecular Imaging | 1 | 2015 | 826 | 0.070 |
Why?
|
Pleural Neoplasms | 1 | 2013 | 612 | 0.070 |
Why?
|
Basement Membrane | 2 | 2005 | 348 | 0.070 |
Why?
|
Reproducibility of Results | 4 | 2020 | 20244 | 0.070 |
Why?
|
Mathematical Computing | 1 | 2007 | 142 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 6 | 2013 | 9081 | 0.070 |
Why?
|
Neurofibromatosis 1 | 1 | 2012 | 561 | 0.070 |
Why?
|
Ovary | 2 | 2001 | 965 | 0.070 |
Why?
|
Mice, Transgenic | 3 | 2016 | 9564 | 0.070 |
Why?
|
Neurilemmoma | 1 | 2012 | 524 | 0.070 |
Why?
|
Lab-On-A-Chip Devices | 1 | 2011 | 446 | 0.070 |
Why?
|
Abdomen | 1 | 2012 | 1137 | 0.070 |
Why?
|
Thoracic Surgery | 1 | 2013 | 729 | 0.070 |
Why?
|
Medical Oncology | 1 | 2018 | 2350 | 0.060 |
Why?
|
Microscopy, Video | 5 | 2013 | 241 | 0.060 |
Why?
|
Disease | 1 | 2011 | 673 | 0.060 |
Why?
|
Rectal Neoplasms | 2 | 2005 | 1183 | 0.060 |
Why?
|
Cytokines | 2 | 2021 | 7453 | 0.060 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2019 | 3116 | 0.060 |
Why?
|
Phenotype | 5 | 2021 | 16735 | 0.060 |
Why?
|
Lymphocyte Activation | 6 | 2002 | 5505 | 0.060 |
Why?
|
Heparitin Sulfate | 2 | 2019 | 224 | 0.060 |
Why?
|
Clinical Chemistry Tests | 1 | 2005 | 59 | 0.060 |
Why?
|
Photography | 1 | 2008 | 537 | 0.060 |
Why?
|
Brain Edema | 1 | 2009 | 607 | 0.060 |
Why?
|
Root Canal Filling Materials | 1 | 2024 | 29 | 0.060 |
Why?
|
DNA Primers | 1 | 2009 | 2827 | 0.060 |
Why?
|
Aluminum Compounds | 1 | 2024 | 56 | 0.060 |
Why?
|
Dental Pulp Cavity | 1 | 2024 | 35 | 0.060 |
Why?
|
Calcium Compounds | 1 | 2024 | 40 | 0.060 |
Why?
|
Silicates | 1 | 2024 | 49 | 0.060 |
Why?
|
RNA, Neoplasm | 2 | 2017 | 751 | 0.060 |
Why?
|
Antibodies, Monoclonal | 7 | 2021 | 9264 | 0.060 |
Why?
|
Flow Cytometry | 3 | 2008 | 5905 | 0.060 |
Why?
|
Caveolins | 1 | 2004 | 102 | 0.060 |
Why?
|
Angiopoietin-1 | 2 | 2004 | 134 | 0.060 |
Why?
|
Receptors, Cell Surface | 2 | 2005 | 2820 | 0.060 |
Why?
|
Carrier Proteins | 1 | 2017 | 4940 | 0.050 |
Why?
|
Biomimetics | 1 | 2005 | 172 | 0.050 |
Why?
|
Receptors, Leukotriene B4 | 1 | 2003 | 93 | 0.050 |
Why?
|
In Situ Nick-End Labeling | 2 | 2018 | 612 | 0.050 |
Why?
|
Brain | 3 | 2020 | 27476 | 0.050 |
Why?
|
Homeostasis | 1 | 2014 | 3348 | 0.050 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2014 | 1756 | 0.050 |
Why?
|
Mice, Knockout | 3 | 2011 | 14485 | 0.050 |
Why?
|
Laminin | 1 | 2024 | 406 | 0.050 |
Why?
|
Male | 14 | 2022 | 365249 | 0.050 |
Why?
|
Antigens, CD | 2 | 2005 | 4032 | 0.050 |
Why?
|
Quinazolines | 1 | 2009 | 1373 | 0.050 |
Why?
|
Glioma | 2 | 2010 | 3532 | 0.050 |
Why?
|
Oxides | 1 | 2024 | 403 | 0.050 |
Why?
|
Ovariectomy | 2 | 2001 | 615 | 0.050 |
Why?
|
Caveolin 1 | 1 | 2004 | 255 | 0.050 |
Why?
|
Leukotriene B4 | 1 | 2003 | 281 | 0.050 |
Why?
|
Blood | 1 | 2005 | 597 | 0.050 |
Why?
|
Cations | 1 | 2002 | 240 | 0.050 |
Why?
|
Microscopy, Electron | 1 | 2005 | 2560 | 0.050 |
Why?
|
Collagen Type I | 1 | 2005 | 620 | 0.050 |
Why?
|
Down-Regulation | 2 | 2011 | 2941 | 0.050 |
Why?
|
Molecular Targeted Therapy | 1 | 2013 | 2830 | 0.050 |
Why?
|
Epithelial Cells | 1 | 2013 | 3701 | 0.050 |
Why?
|
Rotation | 1 | 2003 | 517 | 0.050 |
Why?
|
Female | 17 | 2022 | 397464 | 0.050 |
Why?
|
Salmonella typhimurium | 1 | 2003 | 348 | 0.050 |
Why?
|
Polymerase Chain Reaction | 2 | 2009 | 6085 | 0.050 |
Why?
|
Ultrasonography | 1 | 2014 | 6001 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 4 | 1996 | 4356 | 0.050 |
Why?
|
Pandemics | 1 | 2021 | 8745 | 0.050 |
Why?
|
MicroRNAs | 1 | 2016 | 3811 | 0.040 |
Why?
|
Fibrinogen | 1 | 2024 | 892 | 0.040 |
Why?
|
Graft Survival | 1 | 2011 | 3888 | 0.040 |
Why?
|
Immunity, Innate | 2 | 2024 | 3080 | 0.040 |
Why?
|
Fibrosarcoma | 1 | 2002 | 313 | 0.040 |
Why?
|
von Willebrand Factor | 1 | 2024 | 680 | 0.040 |
Why?
|
Blood Circulation | 1 | 2001 | 248 | 0.040 |
Why?
|
Soft Tissue Neoplasms | 1 | 2009 | 1166 | 0.040 |
Why?
|
Compressive Strength | 1 | 2020 | 159 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 4593 | 0.040 |
Why?
|
Thrombospondin 1 | 1 | 2001 | 257 | 0.040 |
Why?
|
Cell Wall | 1 | 2002 | 421 | 0.040 |
Why?
|
Hydrodynamics | 2 | 2010 | 167 | 0.040 |
Why?
|
Adoptive Transfer | 1 | 2002 | 824 | 0.040 |
Why?
|
Killer Cells, Natural | 2 | 2001 | 2211 | 0.040 |
Why?
|
Rabbits | 3 | 2012 | 4774 | 0.040 |
Why?
|
Tissue Distribution | 1 | 2002 | 2299 | 0.040 |
Why?
|
Doppler Effect | 1 | 2018 | 12 | 0.040 |
Why?
|
Tumor Burden | 2 | 2016 | 1913 | 0.040 |
Why?
|
Mathematics | 2 | 1997 | 704 | 0.040 |
Why?
|
Cattle | 2 | 2001 | 3820 | 0.040 |
Why?
|
Syndecan-1 | 1 | 2019 | 163 | 0.040 |
Why?
|
RNA Interference | 2 | 2017 | 2835 | 0.040 |
Why?
|
Base Sequence | 1 | 2009 | 12430 | 0.040 |
Why?
|
Rats, Sprague-Dawley | 2 | 2006 | 8200 | 0.040 |
Why?
|
Physics | 1 | 2018 | 92 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 6673 | 0.040 |
Why?
|
RNA, Small Interfering | 2 | 2017 | 3433 | 0.040 |
Why?
|
Bone Marrow Cells | 3 | 2011 | 2414 | 0.040 |
Why?
|
Veins | 1 | 2001 | 769 | 0.040 |
Why?
|
Matrix Metalloproteinases | 2 | 2013 | 393 | 0.040 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2000 | 660 | 0.030 |
Why?
|
Mice, Inbred C3H | 3 | 2003 | 915 | 0.030 |
Why?
|
Killer Cells, Lymphokine-Activated | 1 | 1996 | 42 | 0.030 |
Why?
|
Drug Synergism | 1 | 2001 | 1762 | 0.030 |
Why?
|
E-Selectin | 2 | 1996 | 578 | 0.030 |
Why?
|
Uveal Neoplasms | 1 | 2000 | 344 | 0.030 |
Why?
|
P-Selectin | 2 | 1996 | 599 | 0.030 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2019 | 615 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2009 | 4077 | 0.030 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2017 | 221 | 0.030 |
Why?
|
Sulfotransferases | 1 | 2016 | 150 | 0.030 |
Why?
|
Cell Hypoxia | 1 | 2018 | 662 | 0.030 |
Why?
|
Risk Factors | 2 | 2021 | 74971 | 0.030 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 1996 | 1133 | 0.030 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 1996 | 594 | 0.030 |
Why?
|
Cytoplasmic Granules | 1 | 2017 | 574 | 0.030 |
Why?
|
Chemokine CCL2 | 2 | 2009 | 606 | 0.030 |
Why?
|
Photomicrography | 1 | 1993 | 72 | 0.030 |
Why?
|
Monocytes | 1 | 2003 | 2603 | 0.030 |
Why?
|
Nitric Oxide Synthase Type III | 2 | 2011 | 706 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2021 | 5342 | 0.030 |
Why?
|
Convection | 1 | 2013 | 30 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2018 | 10778 | 0.030 |
Why?
|
Signal Transduction | 2 | 2015 | 23652 | 0.030 |
Why?
|
Luminescent Agents | 1 | 2013 | 29 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2016 | 808 | 0.030 |
Why?
|
Partial Pressure | 1 | 2013 | 248 | 0.030 |
Why?
|
omega-N-Methylarginine | 2 | 2005 | 108 | 0.030 |
Why?
|
Peptides | 1 | 2005 | 4353 | 0.030 |
Why?
|
Nanoparticles | 2 | 2018 | 1989 | 0.030 |
Why?
|
Rhodamines | 1 | 2013 | 178 | 0.030 |
Why?
|
Fluorescein-5-isothiocyanate | 1 | 2013 | 222 | 0.030 |
Why?
|
Cell Size | 3 | 2001 | 626 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2023 | 2009 | 0.030 |
Why?
|
Animal Experimentation | 1 | 2012 | 46 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2012 | 5864 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2017 | 1839 | 0.030 |
Why?
|
Neuroprotective Agents | 1 | 2019 | 958 | 0.020 |
Why?
|
Videotape Recording | 1 | 1993 | 336 | 0.020 |
Why?
|
Oxazolone | 1 | 2011 | 61 | 0.020 |
Why?
|
Immunoassay | 1 | 1995 | 746 | 0.020 |
Why?
|
Technology | 1 | 1994 | 296 | 0.020 |
Why?
|
Gelatin | 1 | 2013 | 231 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2018 | 1398 | 0.020 |
Why?
|
Luminescent Measurements | 1 | 2013 | 342 | 0.020 |
Why?
|
Vaccination | 1 | 2024 | 3436 | 0.020 |
Why?
|
Fluorescein Angiography | 2 | 2009 | 1086 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2020 | 3163 | 0.020 |
Why?
|
Models, Animal | 1 | 2018 | 2123 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 1993 | 1629 | 0.020 |
Why?
|
Small Molecule Libraries | 1 | 2017 | 742 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2023 | 3216 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 2018 | 1963 | 0.020 |
Why?
|
Dextrans | 1 | 2013 | 574 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 20776 | 0.020 |
Why?
|
Aged | 2 | 2022 | 171790 | 0.020 |
Why?
|
Whole Body Imaging | 1 | 2012 | 284 | 0.020 |
Why?
|
Nitric Oxide Synthase | 2 | 2005 | 911 | 0.020 |
Why?
|
Chemokine CCL7 | 1 | 2009 | 30 | 0.020 |
Why?
|
Mice, Inbred C57BL | 3 | 2018 | 22381 | 0.020 |
Why?
|
Blotting, Western | 2 | 2009 | 5035 | 0.020 |
Why?
|
Paclitaxel | 1 | 2017 | 1735 | 0.020 |
Why?
|
Gene Expression | 2 | 2016 | 7602 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2017 | 1356 | 0.020 |
Why?
|
Integrin beta Chains | 1 | 2009 | 115 | 0.020 |
Why?
|
Relaxin | 1 | 2009 | 42 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2013 | 2488 | 0.020 |
Why?
|
Image Enhancement | 2 | 2009 | 2898 | 0.020 |
Why?
|
Molecular Probes | 1 | 2010 | 309 | 0.020 |
Why?
|
Microscopy, Fluorescence, Multiphoton | 1 | 2010 | 266 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2009 | 254 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2017 | 1891 | 0.020 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2002 | 1356 | 0.020 |
Why?
|
Tetradecanoylphorbol Acetate | 2 | 2000 | 826 | 0.020 |
Why?
|
Thrombosis | 1 | 2001 | 2956 | 0.020 |
Why?
|
Anisotropy | 1 | 2010 | 1295 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2017 | 2911 | 0.020 |
Why?
|
Receptors, Progesterone | 1 | 2011 | 1159 | 0.020 |
Why?
|
Transduction, Genetic | 1 | 2009 | 902 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6546 | 0.020 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2008 | 690 | 0.020 |
Why?
|
Skull | 1 | 2010 | 830 | 0.020 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 664 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2017 | 12809 | 0.020 |
Why?
|
Ephrin-B2 | 1 | 2004 | 40 | 0.020 |
Why?
|
Tomography, Optical Coherence | 1 | 2018 | 2957 | 0.010 |
Why?
|
Collagen Type IV | 1 | 2004 | 125 | 0.010 |
Why?
|
Receptor, TIE-2 | 1 | 2004 | 182 | 0.010 |
Why?
|
Gamma Rays | 1 | 2004 | 319 | 0.010 |
Why?
|
Combined Modality Therapy | 2 | 2005 | 8559 | 0.010 |
Why?
|
Mesenteric Arteries | 1 | 2003 | 178 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2005 | 899 | 0.010 |
Why?
|
Chemotactic Factors | 1 | 2003 | 197 | 0.010 |
Why?
|
Receptors, Estrogen | 1 | 2011 | 2252 | 0.010 |
Why?
|
Dipeptides | 1 | 2004 | 386 | 0.010 |
Why?
|
Automation | 1 | 2005 | 589 | 0.010 |
Why?
|
Enzyme Inhibitors | 2 | 2005 | 3724 | 0.010 |
Why?
|
Bacterial Adhesion | 1 | 2003 | 305 | 0.010 |
Why?
|
Indium Radioisotopes | 1 | 2002 | 116 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 3814 | 0.010 |
Why?
|
Decorin | 1 | 2001 | 38 | 0.010 |
Why?
|
Stress Fibers | 1 | 2001 | 55 | 0.010 |
Why?
|
Thioglycolates | 1 | 2001 | 37 | 0.010 |
Why?
|
Cytochalasin D | 1 | 2001 | 91 | 0.010 |
Why?
|
Melanoma | 1 | 2000 | 5709 | 0.010 |
Why?
|
Focal Adhesions | 1 | 2001 | 114 | 0.010 |
Why?
|
Fluorouracil | 1 | 2005 | 1655 | 0.010 |
Why?
|
Guinea Pigs | 1 | 2002 | 1309 | 0.010 |
Why?
|
Receptor, erbB-2 | 1 | 2011 | 2606 | 0.010 |
Why?
|
Models, Molecular | 1 | 2010 | 5404 | 0.010 |
Why?
|
Penicillamine | 1 | 2000 | 60 | 0.010 |
Why?
|
Extracellular Space | 1 | 2002 | 566 | 0.010 |
Why?
|
Splenectomy | 1 | 2002 | 392 | 0.010 |
Why?
|
Nitric Oxide Donors | 1 | 2000 | 126 | 0.010 |
Why?
|
Bradykinin | 1 | 2000 | 205 | 0.010 |
Why?
|
Mesenteric Veins | 1 | 2000 | 87 | 0.010 |
Why?
|
Cell Line | 1 | 1993 | 15603 | 0.010 |
Why?
|
Neurons | 1 | 2019 | 9524 | 0.010 |
Why?
|
Luminescent Proteins | 1 | 2002 | 839 | 0.010 |
Why?
|
Staurosporine | 1 | 2000 | 241 | 0.010 |
Why?
|
Antigens | 1 | 2004 | 1444 | 0.010 |
Why?
|
Necrosis | 1 | 2003 | 1621 | 0.010 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 1731 | 0.010 |
Why?
|
Body Water | 1 | 2000 | 340 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2005 | 2920 | 0.010 |
Why?
|
Sex Factors | 1 | 2012 | 10641 | 0.010 |
Why?
|
Species Specificity | 1 | 2002 | 2419 | 0.010 |
Why?
|
Skin | 1 | 2011 | 4507 | 0.010 |
Why?
|
Allantois | 1 | 1997 | 32 | 0.010 |
Why?
|
Antigens, Surface | 1 | 2002 | 1616 | 0.010 |
Why?
|
Fibronectins | 1 | 2001 | 724 | 0.010 |
Why?
|
Organ Specificity | 1 | 2002 | 1970 | 0.010 |
Why?
|
Cartilage | 1 | 2001 | 811 | 0.010 |
Why?
|
Thrombin | 1 | 2000 | 600 | 0.010 |
Why?
|
Chorion | 1 | 1997 | 112 | 0.010 |
Why?
|
Genes, fos | 1 | 1997 | 176 | 0.010 |
Why?
|
Extracellular Matrix Proteins | 1 | 2001 | 835 | 0.010 |
Why?
|
Tetrahydrofolate Dehydrogenase | 1 | 1997 | 133 | 0.010 |
Why?
|
Transfection | 1 | 2004 | 5763 | 0.010 |
Why?
|
Serum Albumin | 1 | 2000 | 677 | 0.010 |
Why?
|
Green Fluorescent Proteins | 1 | 2002 | 2067 | 0.010 |
Why?
|
Membrane Transport Proteins | 1 | 2002 | 1039 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3811 | 0.010 |
Why?
|
Point-of-Care Systems | 1 | 2005 | 1240 | 0.010 |
Why?
|
Spleen | 1 | 2002 | 2294 | 0.010 |
Why?
|
Selectins | 1 | 1995 | 101 | 0.010 |
Why?
|
Up-Regulation | 1 | 2004 | 4148 | 0.010 |
Why?
|
Protein Kinase C | 1 | 2000 | 1207 | 0.010 |
Why?
|
Jurkat Cells | 1 | 1997 | 739 | 0.010 |
Why?
|
Chick Embryo | 1 | 1997 | 975 | 0.010 |
Why?
|
Age Factors | 1 | 2012 | 18454 | 0.010 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 1 | 1996 | 381 | 0.010 |
Why?
|
Glycoproteins | 1 | 2002 | 2202 | 0.010 |
Why?
|
Analog-Digital Conversion | 1 | 1993 | 23 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2000 | 3588 | 0.010 |
Why?
|
Propidium | 1 | 1993 | 42 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2012 | 9442 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2012 | 36861 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2002 | 6232 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2009 | 5707 | 0.010 |
Why?
|
Aorta | 1 | 2000 | 2046 | 0.010 |
Why?
|
Survival Rate | 1 | 2005 | 12873 | 0.010 |
Why?
|
Integrins | 1 | 1995 | 843 | 0.010 |
Why?
|
Actins | 1 | 1997 | 2065 | 0.010 |
Why?
|
Cohort Studies | 1 | 2012 | 41800 | 0.010 |
Why?
|
Retina | 1 | 2000 | 2661 | 0.000 |
Why?
|
DNA Replication | 1 | 1993 | 1428 | 0.000 |
Why?
|
Prognosis | 1 | 2005 | 30044 | 0.000 |
Why?
|
Middle Aged | 2 | 2012 | 223740 | 0.000 |
Why?
|
DNA | 1 | 1993 | 7214 | 0.000 |
Why?
|
Infant, Newborn | 1 | 2000 | 26394 | 0.000 |
Why?
|
Software | 1 | 1993 | 4480 | 0.000 |
Why?
|
Sensitivity and Specificity | 1 | 1993 | 14751 | 0.000 |
Why?
|
Adult | 1 | 2012 | 223818 | 0.000 |
Why?
|